Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShort-Term Debt issuances
Ratios

ImmunityBio (IBRX) EBIAT (2016 - 2026)

ImmunityBio has reported EBIAT over the past 12 years, most recently at -$61.9 million for Q4 2025.

  • Quarterly EBIAT fell 4.46% to -$61.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$351.4 million through Dec 2025, up 15.06% year-over-year, with the annual reading at -$351.4 million for FY2025, 15.05% up from the prior year.
  • EBIAT was -$61.9 million for Q4 2025 at ImmunityBio, up from -$67.3 million in the prior quarter.
  • Over five years, EBIAT peaked at -$59.2 million in Q4 2024 and troughed at -$233.4 million in Q4 2023.
  • The 5-year median for EBIAT is -$95.2 million (2022), against an average of -$105.7 million.
  • Year-over-year, EBIAT crashed 184.01% in 2021 and then surged 74.62% in 2024.
  • A 5-year view of EBIAT shows it stood at -$91.3 million in 2021, then dropped by 17.88% to -$107.6 million in 2022, then crashed by 116.96% to -$233.4 million in 2023, then surged by 74.62% to -$59.2 million in 2024, then dropped by 4.46% to -$61.9 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's EBIAT are -$61.9 million (Q4 2025), -$67.3 million (Q3 2025), and -$92.6 million (Q2 2025).